Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study

MT Newswires Live

Dec 23, 2024

Gain Therapeutics (GANX) said Monday it has received approval in Australia to start a phase 1b trial of GT-02287, the company's lead allosteric small molecule in clinical development to treat Parkinson's disease with or without a GBA1 mutation.

The main objective of the phase 1b trial is to evaluate the safety and tolerability of GT-02287 and follows the completed phase 1 study in healthy volunteers that showed it was safe, well-tolerated and increased glucocerebrosidase activity, the company said.

The company said it expects to complete enrollment for the phase 1b study to be completed in the spring of 2025 and data to be released in the middle of that year.

Shares of Gain Therapeutics were up 17% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2493768493"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2493768493\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2493768493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493768493","market":"nz","top_or_hot":-1,"title":"Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study","media":"MT Newswires Live","content":"<html><body><p> Gain <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (GANX) said Monday it has received approval in Australia to start a phase 1b trial of GT-02287, the company's lead allosteric small molecule in clinical development to treat Parkinson's disease with or without a GBA1 mutation.</p><p>The main objective of the phase 1b trial is to evaluate the safety and tolerability of GT-02287 and follows the completed phase 1 study in healthy volunteers that showed it was safe, well-tolerated and increased glucocerebrosidase activity, the company said.</p><p>The company said it expects to complete enrollment for the phase 1b study to be completed in the spring of 2025 and data to be released in the middle of that year.</p><p>Shares of Gain Therapeutics were up 17% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGain Therapeutics Says Australia Approves Start of Phase 1b Parkinson's Disease Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-23 22:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Gain <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (GANX) said Monday it has received approval in Australia to start a phase 1b trial of GT-02287, the company's lead allosteric small molecule in clinical development to treat Parkinson's disease with or without a GBA1 mutation.</p><p>The main objective of the phase 1b trial is to evaluate the safety and tolerability of GT-02287 and follows the completed phase 1 study in healthy volunteers that showed it was safe, well-tolerated and increased glucocerebrosidase activity, the company said.</p><p>The company said it expects to complete enrollment for the phase 1b study to be completed in the spring of 2025 and data to be released in the middle of that year.</p><p>Shares of Gain Therapeutics were up 17% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XAO.AU","symbol_name":"标普/澳交所 普通股指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493768493","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493768493","pubTimestamp":1734962428,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Gain Therapeutics  said Monday it has received approval in Australia to start a phase 1b trial of GT-02287, the company's lead allosteric small molecule in clinical development to treat Parkinson's disease with or without a GBA1 mutation.The main objective of the phase 1b trial is to evaluate the safety and tolerability of GT-02287 and follows the completed phase 1 study in healthy volunteers that showed it was safe, well-tolerated and increased glucocerebrosidase activity, the company said.The company said it expects to complete enrollment for the phase 1b study to be completed in the spring of 2025 and data to be released in the middle of that year.Shares of Gain Therapeutics were up 17% in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XAO.AU":"标普/澳交所 普通股指数","LENZ":"Therapeutics","XKO.AU":"标普/澳交所 300指数","XJO.AU":"标普/澳交所 200指数","GANX":"Gain Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Gain Therapeutics表示澳大利亚批准启动1b期帕金森病研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XAO.AU":1,"GANX":1,"LENZ":1,"XKO.AU":1,"XJO.AU":1},"content_text":"Gain Therapeutics (GANX) said Monday it has received approval in Australia to start a phase 1b trial of GT-02287, the company's lead allosteric small molecule in clinical development to treat Parkinson's disease with or without a GBA1 mutation.The main objective of the phase 1b trial is to evaluate the safety and tolerability of GT-02287 and follows the completed phase 1 study in healthy volunteers that showed it was safe, well-tolerated and increased glucocerebrosidase activity, the company said.The company said it expects to complete enrollment for the phase 1b study to be completed in the spring of 2025 and data to be released in the middle of that year.Shares of Gain Therapeutics were up 17% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}